|
Volumn 70, Issue 10, 2009, Pages 1473-1474
|
Do glutamatergic agents represent a new class of antidepressant drugs? Part 1
|
Author keywords
[No Author keywords available]
|
Indexed keywords
4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE;
KETAMINE;
LAMOTRIGINE;
METABOTROPIC RECEPTOR AGONIST;
METABOTROPIC RECEPTOR ANTAGONIST;
RILUZOLE;
ALZHEIMER DISEASE;
AMYOTROPHIC LATERAL SCLEROSIS;
ANXIETY DISORDER;
BRAIN DYSFUNCTION;
CLINICAL TRIAL;
DEPRESSION;
DRUG MECHANISM;
DRUG SYNTHESIS;
DRUG TARGETING;
EPILEPSY;
HUMAN;
MAJOR DEPRESSION;
MOOD DISORDER;
NEUROTRANSMISSION;
NONHUMAN;
PATHOPHYSIOLOGY;
PRIORITY JOURNAL;
PSYCHOSIS;
REVIEW;
SCHIZOPHRENIA;
STROKE;
ANIMALS;
ANTIDEPRESSIVE AGENTS;
DEPRESSIVE DISORDER, MAJOR;
DISEASE MODELS, ANIMAL;
DRUG DESIGN;
HUMANS;
NERVE DEGENERATION;
NEURODEGENERATIVE DISEASES;
NEUROPROTECTIVE AGENTS;
RATS;
RECEPTORS, AMPA;
RECEPTORS, METABOTROPIC GLUTAMATE;
RECEPTORS, N-METHYL-D-ASPARTATE;
RILUZOLE;
SYNAPTIC TRANSMISSION;
|
EID: 72849151844
PISSN: 01606689
EISSN: None
Source Type: Journal
DOI: 10.4088/JCP.09ac05680blu Document Type: Review |
Times cited : (9)
|
References (28)
|